Review
Somatostatin analogs in the treatment of acromegaly
Affiliations
- PMID: 1355729
Item in Clipboard
Review
Somatostatin analogs in the treatment of acromegaly
Endocrinol Metab Clin North Am.
1992 Sep.
Abstract
Medical therapy of acromegaly with the somatostatin analog octreotide is very successful. Both clinical symptomatology and hormonal hypersecretion by the growth hormone-secreting pituitary adenomas are controlled, and peripheral IGF-I levels also return to near normal levels. Tumor shrinkage is observed in most patients. Somatostatin analogs can be used after noncurative surgery and for a limited period after radiotherapy, and octreotide pretreatment might improve the outcome of surgery.
Similar articles
-
Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.Acta Neurochir (Wien). 2005 May;147(5):485-93; discussion 493. doi: 10.1007/s00701-005-0511-9. Epub 2005 Apr 4. Acta Neurochir (Wien). 2005. PMID: 15806331 Clinical Trial.
-
Reversible shrinkage of a growth hormone-secreting pituitary adenoma by a long-acting somatostatin analogue, octreotide.Arch Intern Med. 1989 Jun;149(6):1443-5. Arch Intern Med. 1989. PMID: 2730266
-
Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.J Clin Endocrinol Metab. 1994 Nov;79(5):1416-23. doi: 10.1210/jcem.79.5.7962337. J Clin Endocrinol Metab. 1994. PMID: 7962337
-
Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.Neuroendocrinology. 2006;83(3-4):249-57. doi: 10.1159/000095535. Epub 2006 Oct 13. Neuroendocrinology. 2006. PMID: 17047390 Review.
-
Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.J Endocrinol Invest. 2005;28(11 Suppl International):36-42. J Endocrinol Invest. 2005. PMID: 16625843 Review.
Cited by
-
Acromegaly in the elderly patient.Arch Endocrinol Metab. 2019 Nov-Dec;63(6):638-645. doi: 10.20945/2359-3997000000194. Arch Endocrinol Metab. 2019. PMID: 31939489 Free PMC article. Review.
-
Short-term pre-surgical treatment with somatostatin analogues, octreotide and lanreotide, in acromegaly.J Endocrinol Invest. 2000 Jan;23(1):12-8. doi: 10.1007/BF03343669. J Endocrinol Invest. 2000. PMID: 10698045
-
Pituitary tumors. Current concepts in diagnosis and management.West J Med. 1995 Apr;162(4):340-52. West J Med. 1995. PMID: 7747500 Free PMC article. Review.
-
Effectiveness of long-acting octreotide in suppressing hormonogenesis and tumor growth in thyrotropin-secreting pituitary adenomas: report of two cases.Pituitary. 2001 Aug;4(3):135-43. doi: 10.1023/a:1015358721993. Pituitary. 2001. PMID: 12138986
-
A risk-benefit assessment of octreotide in the treatment of acromegaly.Drug Saf. 1997 Nov;17(5):317-24. doi: 10.2165/00002018-199717050-00004. Drug Saf. 1997. PMID: 9391775 Review.